What is the recommended schedule for administering the 13‑valent pneumococcal conjugate vaccine (PCV13) versus the 23‑valent pneumococcal polysaccharide vaccine (PPSV23) in adults?

PCV13 vs PPSV23: Current Vaccination Recommendations

As of 2023, the ACIP no longer recommends routine PCV13 for all adults ≥65 years; instead, adults should receive either a single dose of PCV20 alone OR PCV15 followed by PPSV23 at ≥1 year interval, with PCV13 now relegated to shared clinical decision-making only in select cases. 1

Key Changes from Previous Guidelines

The landscape has fundamentally shifted since 2019. PCV13 is no longer the preferred conjugate vaccine because newer formulations (PCV15, PCV20) provide broader serotype coverage. The 2019 guideline already downgraded PCV13 from routine use to shared clinical decision-making for immunocompetent adults ≥65 years due to minimal population-level impact 2, and the 2023 update effectively supersedes this by prioritizing newer vaccines.

Current Recommended Schedules by Population

Adults ≥65 Years (Vaccine-Naïve)

You have two options 1:

• Option A: Single dose of PCV20 (provides complete coverage, no PPSV23 needed)
• Option B: PCV15 followed by PPSV23 ≥1 year later

The interval matters: While ≥1 year is standard, research shows the 1-year interval provides superior booster effects compared to 6 months, with higher geometric mean fold rises for both IgG and OPA across most serotypes 3. For immunocompromised patients, CSF leak, or cochlear implant, you can shorten to minimum 8 weeks to reduce disease risk 1.

Adults 19-64 Years with Chronic Conditions

Same two-option approach 1:

• Chronic conditions include: alcoholism, chronic heart/liver/lung disease, smoking, diabetes
• Option A: Single PCV20 dose
• Option B: PCV15 then PPSV23 ≥1 year later

Immunocompromised Adults (All Ages)

These patients still require PCV in series with PPSV23 2:

• Includes: asplenia, sickle cell, chronic renal failure, immunodeficiencies, malignancy, HIV, immunosuppression
• Give PCV first, then PPSV23 ≥8 weeks later (can extend to ≥1 year for non-urgent cases)
• At age ≥65, give additional PPSV23 dose if ≥5 years since last PPSV23

What If They Already Received PCV13?

Adults 19-64 with Chronic Conditions Who Got PCV13

• Give PPSV23 ≥1 year after PCV13, OR
• Give PCV20 ≥1 year after PCV13 1
• Reassess at age 65 for additional doses

Adults ≥65 Who Got PCV13 Only

• Complete with either PCV20 (≥1 year after PCV13) OR PPSV23 (≥1 year after PCV13) 1

If They Got Both PCV13 and PPSV23 Before Age 65

• No additional vaccines needed until age 65
• At 65, reassess per current guidelines 1

What If PPSV23 Was Given First?

This is suboptimal but manageable 1:

• Wait ≥1 year, then give PCV15 or PCV20
• Evidence shows PPSV23 blunts subsequent PCV response—OPA GMTs are significantly reduced when PCV13 follows PPSV23 compared to PCV13 alone 4, 5
• This is why PCV should always precede PPSV23 when possible

Sequential Vaccination: The Order Matters

Critical principle: Conjugate vaccines (PCV) must come before polysaccharide vaccines (PPSV23) for optimal immune response. 6

When PCV13 was given first followed by PPSV23 at 1 year, the subsequent PPSV23 response was noninferior to PPSV23 alone 4. However, when PPSV23 was given first, the subsequent PCV13 response was markedly diminished—for example, serotype 4 OPA GMT dropped from 2590 to 988, and serotype 6A dropped from 2947 to 1210 4. This hyporesponsiveness is a well-documented phenomenon with polysaccharide vaccines.

Special Populations

Hematopoietic Stem Cell Transplant Recipients

Completely different schedule 1:

• 3 doses of PCV20, 4 weeks apart, starting 3-6 months post-HSCT
• Fourth dose ≥6 months after third dose OR ≥12 months post-HSCT (whichever later)
• If PCV20 unavailable: 3 doses PCV15 + PPSV23 at ≥12 months (unless chronic GVHD, then 4th PCV15 instead)

Adults ≥65 Without Risk Conditions

• PCV13 moved to shared clinical decision-making in 2019 2
• Consider individual exposure risk and underlying conditions
• Current 2023 guidelines favor PCV20 or PCV15/PPSV23 series over standalone PCV13

Common Pitfalls to Avoid

1. Never co-administer PCV and PPSV23 on same day 2—always separate by appropriate interval
2. Don't give PPSV23 first unless unavoidable—it impairs subsequent PCV response
3. Don't use 6-month interval routinely—1 year provides better immunogenicity 3, though 8 weeks acceptable for high-risk immunocompromised
4. Don't forget to reassess at age 65—patients vaccinated before 65 need additional doses
5. Don't give more than 2 lifetime doses of PPSV23 (one before 65, one at/after 65, separated by ≥5 years) 2

Immunologic Rationale

Why conjugate vaccines are superior: PCVs induce T-cell dependent immune responses with immunologic memory, while PPSV23 induces only T-cell independent responses without memory 1. This explains why:

• PCV responses are more durable
• PCV can be boosted effectively
• PPSV23 causes hyporesponsiveness to subsequent doses
• Sequential PCV→PPSV23 provides both memory and broader serotype coverage

The 2023 guidelines reflect recognition that PCV13 covered only 13 serotypes while PCV20 covers 20, and PPSV23's 11 unique serotypes still account for 32-37% of invasive disease in adults ≥65 2. The combination strategy maximizes serotype coverage while leveraging conjugate vaccine immunologic advantages.